Skip Navigation


European Heart Journal Advance Access originally published online on September 1, 2005
European Heart Journal 2005 26(20):2079-2080; doi:10.1093/eurheartj/ehi477
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/20/2079    most recent
ehi477v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nattel, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nattel, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Aldosterone antagonism and atrial fibrillation: time for clinical assessment?

Stanley Nattel1,2,*

1Department of Medicine and Research Center, Montreal Heart Institute and University of Montreal, 5000 Belanger St E., Montreal, Quebec, Canada H1T 1C8
2Department of Pharmacology and Therapeutics, McGill University, Canada

* Corresponding author. Tel: +1 514 376 3330; fax: +1 514 376 1355. E-mail address: stanleynattel@aol.com

This editorial refers to ‘Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction’{dagger} by P. Milliez et al., on page 2193

The first 10% of the full text of this article appears below.

Atrial fibrillation (AF) is the most common sustained clinical arrhythmia. Presently available therapy for AF is suboptimal: ‘rhythm control’ drugs are fraught with the risk of pro-arrhythmia and other adverse effects, ‘rate control’ leaves the atria fibrillating and fails to reproduce physiological heart rate adaptation, and ablation procedures are expensive, complex, and incompletely effective. Over the past few years, the notion of ‘upstream’ therapy, targeting signalling pathways involved in the development of the substrate that supports the arrhythmia,1 has gained increased interest, supported by experimental2 and clinical3 studies which indicate that suppression . . . [Full Text of this Article]

Acknowledgement


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction
Paul Milliez, Noeleen DeAngelis, Catherine Rucker-Martin, Antoine Leenhardt, Eric Vicaut, Estelle Robidel, Philippe Beaufils, Claude Delcayre, and Stéphane N. Hatem
EHJ 2005 26: 2193-2199. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 EuropaceHome page
A. Bukowska, U. Lendeckel, A. Krohn, G. Keilhoff, S. t. Have, K. H. Neumann, and A. Goette
Atrial fibrillation down-regulates renal neutral endopeptidase expression and induces profibrotic pathways in the kidney
Europace, October 1, 2008; 10(10): 1212 - 1217.
[Abstract] [Full Text] [PDF]